Biodesix Appoints Jean Franchi and Hany Massarany to Board of Directors
BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. a leader in lung cancer diagnostics, today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Ms. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Mr. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.
“Jean and Hany both have exceptional strategic expertise, which will be invaluable for Biodesix as we move into a new phase of growth,” said Scott Hutton, Biodesix CEO. “They both have proven track records demonstrating their ability to see the big picture and streamline financial and organizational operations. This experience will complement Biodesix’s existing capabilities, making us better equipped to provide the vital diagnostic tools for which we are known.”
Ms. Franchi currently serves as chief financial officer for Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies. She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme, where she supported the company during its most rapid growth phase. Ms. Franchi served as chief financial officer at numerous other public and private companies before joining Replimune Group in 2019. Ms. Franchi earned a bachelor’s degree in business administration from Hofstra University.
Mr. Massarany served as president and chief executive officer of GenMark Diagnostics, Inc. (NASDAQ: GNMK) from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009, Mr. Massarany was responsible for various global leadership positions with Ventana. He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics, working in Asia Pacific and the United States. Mr. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University, Australia and an MBA from Melbourne University, Australia.
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy consisting of the Nodify XL2™ test and the Nodify CDT™ test evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit www.biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Biodesix operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Jordona Jackson Smith for Biodesix